Search

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

25.97 1.96

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

25.38

Max

26.29

Pagrindiniai rodikliai

By Trading Economics

Pajamos

191K

-51M

Pardavimai

6.7M

106M

Pelnas, tenkantis vienai akcijai

-0.46

Pelno marža

-47.808

Darbuotojai

1,784

EBITDA

-2.1M

-46M

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+28.09% upside

Dividendai

By Acuity

Kitas uždarbis

2026-11-05

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

593M

2.6B

Ankstesnė atidarymo kaina

24.01

Ankstesnė uždarymo kaina

25.97

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-13 23:56; UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

2026-08-13 23:56; UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

2026-08-13 23:51; UTC

News

Milestone Scientific reported second-quarter sales of $2.841 million, exceeding estimates. Shares are higher in after-market hours following the earnings announcement.

2026-08-13 23:51; UTC

News
Social Media

Campbell Soup Co filed for a mixed securities shelf to raise capital. Shares are higher in after-market trading amid positive social media sentiment.

2026-08-13 23:51; UTC

News
Social Media

Charter Communications received final approval for its Cox acquisition, but shares are trading lower in after-market hours, reflecting downward pressure since Thursday's close.

2026-08-13 23:46; UTC

News

Citi analyst Ronald Josey raised Wayfair's price target to $133.00 from $95.00, maintaining a Buy rating. Shares are trading higher in after-market hours.

2026-08-13 23:46; UTC

News
Correlated Moves

Synchrony Financial shares declined in after-market hours following the appointment of Nimrod Barak as Chief AI Officer, effective June 30, 2026.

2026-08-13 23:46; UTC

News

UWM Holdings Corp secures $2.05 billion investment from Oaktree and SFS Group. Shares are trading higher in after-market hours following the announcement.

2026-08-13 23:41; UTC

News

EPR Properties declared a monthly cash dividend of $0.31 per share, payable September 15, 2026, as shares moved higher during after-market hours.

2026-08-13 23:41; UTC

News

Credicorp Ltd reported second-quarter earnings of $7.29 per share, exceeding estimates. The stock moved higher during after-market hours following this performance.

2026-08-13 23:41; UTC

Social Media
News

Eton Pharmaceuticals reported record revenue of $37.6 million and raised its full-year guidance to over $145 million, driving shares higher in after-market trading.

2026-08-13 23:41; UTC

News

Norway's sovereign wealth fund increased its Bitcoin exposure through MicroStrategy investments. Bitcoin is trading lower today, remaining below its 20-day moving average.

2026-08-13 23:36; UTC

News

Lucid Group Inc introduced the Lucid Gravity GT-S SUV priced at $125,900, but shares declined in after-market trading following the announcement.

2026-08-13 23:31; UTC

News

Western Union shares rise in after-market trading following New York Governor Kathy Hochul's approval of its acquisition of International Money Express.

2026-08-13 23:31; UTC

Correlated Moves
News
Social Media

Microsoft shares are trading lower after a report on OpenAI's $40 billion revenue run rate and Iren's $9.7 billion cloud services contract.

2026-08-13 23:31; UTC

Social Media
News

Micron Technology launches a $250 million AI-focused fund, raising total commitments to $550 million. Shares are trading higher in after-market hours.

2026-08-13 23:31; UTC

News
Social Media

Nu Holdings Ltd shares rose in after-market trading following strong Q2 results, with revenue of $5.9 billion surpassing estimates and net profit reaching $1.06 billion.

2026-08-13 23:26; UTC

News

CoreCivic Inc shares rose in after-market trading following positive analyst ratings updates and a raised price target from Benchmark Co. to $45.00.

2026-08-13 23:26; UTC

Correlated Moves
News

Diodes Inc announced a $325 million private placement of convertible senior notes due 2031. Shares are lower in after-market trading amid broader market trends.

2026-08-13 23:26; UTC

News

Hewlett Packard Enterprise shares rose in after-market trading, buoyed by positive sentiment from Cisco's earnings and broader market gains.

2026-08-13 23:21; UTC

News

Knight-Swift Transportation affirms quarterly cash dividend of $0.20 per share, though shares are trading lower in after-market hours.

2026-08-13 23:21; UTC

News

Rapid7 Inc shares rose in after-market trading after reporting adjusted EPS of $0.44, exceeding expectations, and raising full-year guidance to $1.81.

2026-08-13 23:16; UTC

News
Correlated Moves

Citigroup's U.S. Consumer Cards business will acquire Kard Financial to enhance credit card rewards for its 70 million cardmembers. Shares are little changed in after-market trading.

2026-08-13 23:16; UTC

Correlated Moves
News

Sunrun Inc. shares declined in after-market trading, reflecting broader market trends. Recent financial results showed sales of $543.73 million and revenue of $869.99 million.

2026-08-13 23:16; UTC

News

Jack in the Box Inc shares rose in after-market trading following UBS and Citigroup raising their price targets to $20, indicating a stable outlook.

2026-08-13 23:11; UTC

News

Sabre Corp reported second-quarter revenue of $712 million and raised its full-year profitability outlook, though shares are trading lower in after-market hours.

2026-08-13 23:06; UTC

Social Media
News

Tesla shares gained in after-market hours following the end of a lengthy strike by IF Metall and as Michael Burry covered his short position.

2026-08-13 23:06; UTC

News

Silicon Motion Technology closed a $1.15 billion offering of Convertible Senior Notes due 2031, with shares trading higher in after-market hours.

2026-08-13 23:06; UTC

News
Event

Target Corp will announce Q2 FY2026 earnings on August 19, with an estimated EPS of $2.24 and revenue of $25.7 billion. Shares showed little change after hours.

2026-08-13 23:02; UTC

Social Media
News

Cboe Global Markets announced a dividend increase to $0.86 per share, effective September 15, 2026. Shares are trading higher in after-market hours.

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

28.09% į viršų

12 mėnesių prognozė

Vidutinis 32.65 USD  28.09%

Aukščiausias 45 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

3

Pirkti

1

Laikyti

0

Parduoti

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat